rhC1INH

rhC1INH, also known as recombinant human C1 inhibitor, is a protein produced through recombinant DNA technology. It is a modified version of the natural human C1 inhibitor, which is a key component of the complement system, a part of the body's immune response. The complement system helps to identify and destroy pathogens, such as bacteria and viruses, that have invaded the body.

rhC1INH is used primarily in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by the destruction of red blood cells. In PNH, the body's complement system is activated, leading to the destruction of red blood cells. rhC1INH works by inhibiting the complement system, thereby preventing the destruction of red blood cells and reducing the symptoms of PNH.

The production of rhC1INH involves the insertion of the gene for human C1 inhibitor into a host cell, such as Chinese hamster ovary (CHO) cells. The host cells are then cultured in a bioreactor, where they produce the recombinant protein. The rhC1INH is then purified from the culture medium and formulated into a sterile, non-pyrogenic solution for injection.

rhC1INH is administered intravenously and has a half-life of approximately 24 hours. It is typically given once every two weeks. The most common side effects of rhC1INH include injection site reactions, headache, and nausea. Serious side effects are rare but can include anaphylaxis and infusion-related reactions.

rhC1INH is a valuable treatment option for patients with PNH, as it can help to reduce the symptoms of the disorder and improve the quality of life. However, it is important to note that rhC1INH is not a cure for PNH and that the underlying cause of the disorder is not addressed by the treatment. Therefore, it is typically used in combination with other treatments, such as red blood cell transfusions and immunosuppressive therapies.